The sensitivity of rapid diagnostic tests (RDT) for Chagas disease is not great enough for their single use. The aim of this paper was to evaluate the performance of two RDTs for Chagas disease, used simultaneously. Two different RDTs (A and B) were performed in 64 and 42 serum samples that were negative and positive, respectively, by conventional serological techniques. Validity and reliability of both tests were evaluated individually and simultaneously. Sensitivity was 90.5% and 97.6%, and specificity was 100% and 93.8%, for RDT A and B, respectively. The k statistic was 0.96. When both RDTs were used simultaneously, sensitivity was 97.4%, specificity was 100% and the discordance percentage 6.6%. The combined use of two RDTs with serum samples is an acceptable application in healthcare centres.
The use of chimeric molecules fusing several antigenic determinants is a promising strategy for the development of low-cost, standardized and reliable kits to determine specific antibodies. In this study, we designed and assessed a novel recombinant chimera that complements the performance of our previously developed chimera, CP1 [FRA and SAPA antigens (Ags)], to diagnose chronic Chagas disease. The new chimeric protein, named CP3, is composed of MAP, TcD and TSSAII/V/VI antigenic determinants. We compared the performance of both chimeric Ags using a panel of 67 Trypanosoma cruzi-reactive sera and 67 non-reactive ones. The sensitivity of CP3 vs CP1 was 100 and 90.2%, and specificity was 92.5 and 100%, respectively. The mixture of CP1 + CP3 achieved 100% of sensitivity and specificity. More importantly, an additional subset of 17 sera from patients with discordant results of conventional serological methods was analysed; the CP1 + CP3 mixture allowed us to accurately classify 14 of them with respect to IIF, the usual technique used in most of the reference centres. These results show an improved performance of the CP1 + CP3 mixture in comparison with enzyme-linked immunosorbent assay and indirect haemagglutination commercial assays.
Many patients with Chagas disease live in remote communities that lack both equipment
and trained personnel to perform a diagnosis by conventional serology (CS). Thus,
reliable tests suitable for use under difficult conditions are required. In this
study, we evaluated the ability of personnel with and without laboratory skills to
perform immunochromatographic (IC) tests to detect Chagas disease at a primary health
care centre (PHCC). We examined whole blood samples from 241 patients and serum
samples from 238 patients. Then, we calculated the percentage of overall agreement
(POA) between the two groups of operators for the sensitivity (S), specificity (Sp)
and positive (PPV) and negative (NPV) predictive values of IC tests compared to CS
tests. We also evaluated the level of agreement between ELISAs and indirect
haemagglutination (IHA) tests. The readings of the IC test results showed 100%
agreement (POA = 1). The IC test on whole blood showed the following values: S =
87.3%; Sp = 98.8%; PPV = 96.9% and NPV = 95.9%. Additionally, the IC test on serum
displayed the following results: S = 95.7%; Sp = 100%; PPV = 100% and NPV = 98.2%.
Using whole blood, the agreement with ELISA was 96.3% and the agreement with IHA was
94.1%. Using serum, the agreement with ELISA was 97.8% and the agreement with IHA was
96.6%. The IC test performance with serum samples was excellent and demonstrated its
usefulness in a PHCC with minimal equipment. If the IC test S value and NPV with
whole blood are improved, then this test could also be used in areas lacking
laboratories or specialised personnel.
Dengue virus (DENV) transmission occurs primarily in tropical and subtropical climates, but within the last decade it has extended to temperate regions. Santa Fe, a temperate province in Argentina, has experienced an increase in dengue cases and virus circulation since 2009, with the recent 2020 outbreak being the largest in the province to date. The aim of this work is to describe spatio-temporal fluctuations of dengue cases from 2009 to 2020 in Santa Fe Province. The data presented in this work provide a detailed description of DENV transmission for Santa Fe Province by department. These data are useful to assist in investigating drivers of dengue emergence in Santa Fe Province and for developing a better understanding of the drivers and the impacts of ongoing dengue emergence in temperate regions across the world. This work provides data useful for future studies including those investigating socio-ecological, climatic, and environmental factors associated with DENV transmission, as well as those investigating other variables related to the biology and the ecology of vector-borne diseases.
Background: In Latin America, Chagas disease is endemic, with a high prevalence in rural indigenous communities and an increasing prevalence in urban areas owing to migration from rural areas with active vector transmission. This study aimed to assess differences in the prevalence of Chagas disease in urban and rural moqoit communities, one of the main ethnic indigenous groups in the south of Gran Chaco.Methods: A seroprevalence study was conducted in six moqoit populations in the Santa Fe province, Argentina. The variables studied were serology results for Chagas disease, residents of urban or rural areas, age, and sex.
Results:The results showed that 9.26% of the 702 volunteers evaluated and 18.32% of the 131women of childbearing potential were seropositive. According to the calculated prevalence ratio, the prevalence of Chagas disease in urban communities was6.41 (95% confidence inverval: 3.73-11.02) times higher than that in rural communities: 21.59% in urban communities vs. 3.37%in rural communities.
Conclusions:The seroprevalence found in the moqoit community was higher than the estimated level for the general population of the same region, with a greater impact in urban areas than in rural areas. The urbanization of groups of people with poor socio-sanitary conditions in the second half of the 20th century could have caused this higher seroprevalence of Chagas disease.
<strong>Introducción. </strong><span>La Enfermedad de Chagas (ECh) es endémica en la Región del Chaco. Se desconoce su seroprevalencia en mayores de 14 años de áreas rurales del Chaco Santafesino. El objetivo del trabajo fue determinar la seroprevalencia de ECh en mayores de 14 años de áreas rurales del Chaco Santafesino, Argentina, y su asociación con factores de riesgo epidemiológico. </span><strong>Métodos</strong><span>. Se realizó un estudio transversal entre 2010 y 2015, en personas mayores de 14 años, los distritos rurales de la región del Chaco, en el Norte de la Provincia de Santa Fe, Argentina. Se determinó la prevalencia de anticuerpos contra </span><em>Trypanosoma cruzi</em><span> mediante dos pruebas serológicas, realizando una tercera en caso de discordancia. Se realizaron encuestas semiestructuradas sobre variables socioambientales. Se analizó la asociación entre ECh y variables socioambientales mediante la razón de prevalencias con un intervalo de confianza del 95%. </span><strong>Resultados</strong><span>. Se estudió una muestra de 749 personas, con una media de edad de 29,5 años. La seroprevalencia fue de 24,70% (26,69% en mujeres y 20,26% en hombres). Se halló asociación estadísticamente significativa entre las variables socioambientales y la seroprevalencia. La seroprevalencia fue 7,83 veces mayor en los hijos de madres que no habían alcanzado la educación secundaria. </span><strong>Conclusiones</strong><span>. La región del Chaco Santafesino es endémica para Chagas, al igual que otras provincias de la Región. El bajo nivel de instrucción materno es el condicionante más importante para esta endemia.</span>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.